Precision Cancer Medicine at China's Premier Cancer Center
The Department of Medical Oncology at Fudan University Shanghai Cancer Center (FUSCC) is one of China's most distinguished and research-active medical oncology programs, with a national reputation for excellence in precision oncology, immunotherapy, antibody-drug conjugates, and the management of advanced and metastatic cancers across all tumor types. As the systemic therapy backbone of one of China's highest-volume cancer centers, the medical oncology department combines outstanding clinical expertise with one of the most productive cancer research programs in Asia, offering international patients access to the latest evidence-based treatments, novel investigational therapies, and clinical trials.
For international patients with advanced cancer — whether seeking expert systemic therapy, a second opinion on treatment strategy, access to novel targeted agents or immunotherapy, or enrollment in clinical trials — FUSCC's medical oncology department offers an unparalleled combination of expertise, research leadership, and multidisciplinary integration. China Medical Concierge Shanghai (CMCS) provides seamless end-to-end coordination for international patients throughout their care journey at FUSCC.
About the Department
FUSCC's medical oncology department is a national key clinical specialty operating a comprehensive chemotherapy and immunotherapy infusion center, dedicated inpatient oncology wards, a precision oncology and molecular tumor board, subspecialty clinics for breast cancer, lung cancer, gastrointestinal cancers, gynecologic cancers, and other tumor types, and one of China's most active cancer clinical trial programs. The department works in close collaboration with all surgical oncology departments, radiation oncology, pathology, and molecular diagnostics through fully integrated multidisciplinary tumor boards.
Faculty members publish regularly in the world's leading oncology journals including New England Journal of Medicine, Lancet Oncology, Journal of Clinical Oncology, Nature Medicine, Cancer Cell, and Annals of Oncology.
Systemic Therapy Expertise
Targeted Therapy
FUSCC's medical oncology department has extensive experience with the full range of approved targeted therapies across all major tumor types:
Lung Cancer
- EGFR-Mutated NSCLC — Osimertinib (first and third-generation); amivantamab + lazertinib for osimertinib-resistant EGFR-mutated NSCLC; patritumab deruxtecan for HER3-expressing EGFR-mutated NSCLC
- ALK-Positive NSCLC — Alectinib, brigatinib, lorlatinib; resistance mechanism-guided sequential therapy
- KRAS G12C NSCLC — Sotorasib, adagrasib; combination strategies for acquired resistance
- MET Exon 14 NSCLC — Tepotinib, capmatinib, savolitinib
- RET-Fused NSCLC — Selpercatinib, pralsetinib
- NTRK-Fused NSCLC — Larotrectinib, entrectinib
- BRAF V600E NSCLC — Dabrafenib + trametinib
- HER2-Mutated NSCLC — Trastuzumab deruxtecan (T-DXd)
Breast Cancer
- HER2-Positive — Trastuzumab + pertuzumab; T-DM1; T-DXd; tucatinib + capecitabine + trastuzumab for brain metastases; margetuximab
- HR-Positive/HER2-Negative — CDK4/6 inhibitors (palbociclib, ribociclib, abemaciclib); alpelisib for PIK3CA-mutated; capivasertib + fulvestrant for PIK3CA/AKT1/PTEN-altered; elacestrant for ESR1-mutated; inavolisib combinations
- TNBC — Pembrolizumab + chemotherapy; sacituzumab govitecan; olaparib/talazoparib for BRCA-mutated; datopotamab deruxtecan
Gastrointestinal Cancers
- Colorectal — Cetuximab/panitumumab for RAS/BRAF WT; encorafenib + cetuximab for BRAF V600E; trastuzumab combinations for HER2-amplified; fruquintinib; trifluridine/tipiracil
- Gastric/GEJ — Trastuzumab; T-DXd; zolbetuximab; bemarituzumab; ramucirumab
- Cholangiocarcinoma — Ivosidenib (IDH1); pemigatinib/infigratinib/futibatinib (FGFR2); erdafitinib
- HCC — Atezolizumab + bevacizumab; lenvatinib; sorafenib; regorafenib; cabozantinib; ramucirumab
- Pancreatic — Olaparib for BRCA-mutated; KRAS G12D inhibitors in trials
Immunotherapy
FUSCC's medical oncology department has extensive experience with cancer immunotherapy across all approved indications and beyond:
- PD-1/PD-L1 Checkpoint Inhibitors — Pembrolizumab, nivolumab, atezolizumab, durvalumab, sintilimab, camrelizumab, tislelizumab across multiple tumor types; biomarker-guided patient selection (PD-L1, TMB, MSI)
- CTLA-4 Inhibitors — Ipilimumab in combination with nivolumab for melanoma, RCC, NSCLC, HCC, and other tumors
- LAG-3 Inhibitors — Relatlimab + nivolumab for melanoma
- Bispecific T-Cell Engagers — Mosunetuzumab, glofitamab, epcoritamab for B-cell lymphoma; tarlatamab for SCLC
- irAE Management — Expert management of immune-related adverse events leveraging FUSCC's multidisciplinary subspecialty network; steroid protocols and immunosuppressive therapy for severe irAEs
Antibody-Drug Conjugates (ADCs)
FUSCC is one of China's most experienced centers for ADC therapy, with expertise across the rapidly expanding ADC landscape:
- HER2-Targeting ADCs — Trastuzumab deruxtecan (T-DXd) for HER2-positive and HER2-low breast, gastric, lung, and colorectal cancer; trastuzumab emtansine (T-DM1) for HER2-positive breast cancer
- TROP2-Targeting ADCs — Sacituzumab govitecan for TNBC and urothelial cancer; datopotamab deruxtecan for breast and lung cancer
- Nectin-4-Targeting ADCs — Enfortumab vedotin for urothelial cancer
- FRα-Targeting ADCs — Mirvetuximab soravtansine for ovarian cancer
- CD79b-Targeting ADCs — Polatuzumab vedotin for diffuse large B-cell lymphoma
- ADC Toxicity Management — Expert management of ADC-specific toxicities including interstitial lung disease, peripheral neuropathy, and ocular toxicity
PARP Inhibitors
- Ovarian Cancer — Olaparib, niraparib, rucaparib for maintenance and treatment
- Breast Cancer — Olaparib and talazoparib for BRCA-mutated metastatic breast cancer
- Prostate Cancer — Olaparib and rucaparib for HRR-mutated mCRPC
- Pancreatic Cancer — Olaparib maintenance for BRCA-mutated metastatic PDAC
Precision Oncology & Molecular Tumor Board
FUSCC's precision oncology program is one of the most advanced in China:
- Comprehensive Genomic Profiling (CGP) — NGS panel testing of 300-500+ cancer genes; identification of actionable mutations, fusions, copy number alterations, and TMB/MSI
- Liquid Biopsy (ctDNA) — Cell-free DNA analysis for treatment monitoring, resistance mechanism identification, and MRD detection
- RNA Sequencing — For fusion detection and gene expression profiling
- Proteomics & Phosphoproteomics — Research-grade multi-omics profiling for complex cases
- Molecular Tumor Board — Weekly multidisciplinary review of complex molecular profiling results; identification of off-label targeted therapy options and clinical trial eligibility
- Tumor Mutational Burden (TMB) — Pembrolizumab for TMB-high solid tumors
- NTRK Fusion Testing — Larotrectinib and entrectinib for tumor-agnostic NTRK-fused cancers
- RET Fusion Testing — Selpercatinib for tumor-agnostic RET-fused cancers
Clinical Trials: Access to Tomorrow's Treatments
FUSCC is one of China's most active cancer clinical trial centers, with one of the largest portfolios of ongoing oncology trials in the country. For international patients, this means potential access to investigational agents not yet widely available:
- Novel ADCs targeting emerging antigens (HER3, B7-H3, CEACAM5, DLL3, and others)
- Next-generation KRAS inhibitors (G12D, G12V, pan-KRAS)
- Novel immunotherapy combinations and bispecific antibodies
- CAR-T cell therapy for solid tumors
- Tumor-infiltrating lymphocyte (TIL) therapy
- Novel PARP inhibitor combinations
- Oral SERD and SERD combinations for HR-positive breast cancer
Why International Patients Choose FUSCC Medical Oncology
- Research Leadership — Publications in NEJM, Lancet Oncology, and Nature Medicine; landmark contributions to breast cancer, lung cancer, and GI oncology
- ADC Expertise — One of China's most experienced centers for the full range of approved and investigational ADCs
- Precision Oncology — Comprehensive molecular tumor board with CGP, liquid biopsy, and multi-omics profiling
- Clinical Trial Access — One of China's largest oncology trial portfolios with access to novel investigational agents
- irAE Management — Expert immunotherapy toxicity management leveraging FUSCC's multidisciplinary network
- Cost-Effectiveness — World-class cancer medicine at significantly lower cost than equivalent treatment in Western countries
The CMCS Patient Journey
- Initial Inquiry — Share your cancer diagnosis, pathology reports, molecular profiling results, imaging, prior treatment history, and current medications with CMCS.
- Medical Record Preparation — We translate and organize your records for specialist pre-consultation review.
- Specialist Matching — We identify the most appropriate medical oncologist based on your tumor type and molecular profile.
- Molecular Tumor Board Submission — Where appropriate, we facilitate pre-arrival case review by FUSCC's molecular tumor board.
- Priority Scheduling — We secure a consultation with minimal waiting time.
- Travel & Logistics — Assistance with visa invitation letters, accommodation near FUSCC, and Shanghai airport transfers.
- Treatment Coordination — Full coordination of molecular profiling, imaging, infusion scheduling, and clinical trial enrollment.
- Post-Treatment Follow-Up — Treatment response assessment, molecular profiling report translation, and remote follow-up after you return home.
Book a Consultation
If you are seeking expert medical oncology care in Shanghai — whether for advanced breast cancer, lung cancer, GI cancer, gynecologic cancer, or any solid tumor requiring precision systemic therapy — CMCS can arrange a specialist consultation with FUSCC's medical oncology team.
📧 contract@medicalsh.com
💬 WhatsApp: https://wa.me/message/3AM6KAGCW2BAD1
🌐 www.medicalsh.com
0 comentarios